Arrhythmia

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations. Read More

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities. Read More

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions. Read More

In addition to establishing potency, the team’s tests on cells and, later, mice showed that even high doses of the compound caused no ill effects. Read More

Structural views of the proteins that regulate the heartbeat may help improve existing treatments for cardiac arrhythmias. Read More

Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia. Read More

Björn Knollmann, M.D., Ph.D., has been named director of the newly formed Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART). Read More

A particular anti-arrhythmia drug provides a targeted treatment for certain forms of atrial fibrillation. Read More

Reducing heart muscle response to calcium could decrease the risk of fatal arrhythmias after heart attacks. Read More

A genetic variant that increases risk for atrial fibrillation also impacts the response to a common therapy for the heart rhythm disorder. Read More

The state of Michael Stanbery’s health was shocking. Read More

A team led by Vanderbilt University investigators has discovered two new genes — both coding for the signaling protein calmodulin — associated with severe early-onset disorders of heart rhythm. Read More

The main antioxidant compound in green tea increases contractile force in isolated heart cells, suggesting it may be useful in heart failure. Read More

Females may be at higher risk of potentially fatal heart condition due to gender differences in a protein involved in the heart’s electrical activity. Read More

Vanderbilt researchers have discovered a rare, but important risk posed by the antibiotic azithromycin, commonly called a “Z-pack.” The study found a 2.5-fold higher risk of death from cardiac arrhythmia in the first five days of taking azithromycin when compared with another common antibiotic or no antibiotics at all. Read More

Individuals with atrial fibrillation who have a particular genetic variant respond better to rate control therapy. Read More